Phaseline

Companies › HTA

HTA: clinical trials, targets and expected readouts

3 active drug programs in 6 registered trials: 3 Phase 3, 3 Phase 2; Other, Neurology, Metabolic and endocrine, Oncology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Lutetium Oxodotreotide Lu-177
Somatostatin receptor binding agent
SSTR5, SSTR2, SSTR4, SSTR1, SSTR3Phase 3NETS Ga68 Lu177Nov 2026
[18F]Fluorbetazine injection
PET tracer for amyloid-beta plaque imaging
APPPhase 3Mild Cognitive Impairment (MCI)Dec 2027
68Ga-DOTATATE Injection
Somatostatin receptor 2 (SSTR2) agonist/imaging agent
SSTR2Phase 3NETs; Healthy (Controls); Metastic Thyroid Cancer; ACTH–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT0711924268Ga-DOTATATE InjectionPhase 3NETsOtherNov 2024
NCT07057622Lutetium Oxodotreotide Lu-177Phase 3NETS Ga68 Lu177OtherNov 2026
NCT07764679[18F]Fluorbetazine injectionPhase 3Mild Cognitive Impairment (MCI)NeurologyDec 2027
NCT0728458968Ga-DOTATATE InjectionPhase 2Healthy (Controls)OncologyApr 2030
NCT0492741668Ga-DOTATATE InjectionPhase 2Metastic Thyroid CancerOncologyNov 2030
NCT0201970668Ga-DOTATATE InjectionPhase 2ACTHMetabolic and endocrineDec 2030

Targets

SSTR2 (2) SSTR5 (1) SSTR4 (1) SSTR1 (1) SSTR3 (1) APP (1)

Companies with the same targets

Novartis Sinotau Pharmaceutical Group RayzeBio Advanced Accelerator Applications CSPC ZhongQi Pharmaceutical Technology RECORDATI GROUP ITM Solucin Debiopharm International Alnylam Pharmaceuticals Roche

Companies built like this

AgelessRx Biotechnology Institute IMASD Epygenix Huons Biopharma Neuren Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.